ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,675.68
1.18%
Gold vs US Dollar
2,302.57
0.00%
Brent Oil
82.765
0.00%
Bitcoin
64,281.68
2.21%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Akari Therapeutics PLC (AKTX)

  7. Akari Therapeutics PLC (AKTX) News

Akari Therapeutics (AKTX)

Akari Therapeutics PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AKTX
DateTimeSourceHeadlineSymbolCompany
15/03/202416:53PR Newswire (US)Kuehn Law Encourages VIVK, MINM, SDPI, and AKTX Investors to Contact Law FirmNASDAQ:AKTXAkari Therapeutics PLC
11/03/202421:25Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:AKTXAkari Therapeutics PLC
11/03/202421:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
05/03/202421:57Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:AKTXAkari Therapeutics PLC
05/03/202413:34Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:AKTXAkari Therapeutics PLC
05/03/202413:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
09/01/202422:25Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:AKTXAkari Therapeutics PLC
04/01/202417:34Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
03/01/202401:06Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
03/01/202400:56Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
03/01/202400:49Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
02/01/202423:58Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
02/01/202423:41Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
02/01/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
01/12/202313:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AKTXAkari Therapeutics PLC
16/11/202313:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AKTXAkari Therapeutics PLC
27/10/202321:15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:AKTXAkari Therapeutics PLC
27/10/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AKTXAkari Therapeutics PLC
24/10/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AKTXAkari Therapeutics PLC
24/10/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AKTXAkari Therapeutics PLC
20/10/202322:00Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
20/10/202321:29Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:AKTXAkari Therapeutics PLC
20/10/202321:28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:AKTXAkari Therapeutics PLC
20/10/202321:23Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:AKTXAkari Therapeutics PLC
19/10/202321:17Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:AKTXAkari Therapeutics PLC
12/10/202321:43Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AKTXAkari Therapeutics PLC
29/09/202313:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AKTXAkari Therapeutics PLC
21/09/202313:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AKTXAkari Therapeutics PLC
05/09/202314:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AKTXAkari Therapeutics PLC
18/08/202313:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AKTXAkari Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:AKTX

Your Recent History

LSE
SCLP
Scancell
LSE
AGL
Angle
LSE
EEE
Empire Metals
LSE
FUM
Futura Medical
LSE
AAU
Ariana Resources
LSE
PHNX
Phoenix
LSE
SCE
Surface Transforms
LSE
GFM
Griffin Mining
LSE
TERN
Tern
LSE
YU.
Yu
LSE
HARL
Harland & Wolff
LSE
CNR
Condor Gold
LSE
MIN
Minoan
LSE
JEMA
Jpmorgan Emerging Europe...
LSE
AAZ
Anglo Asian Mining
LSE
GKP
Gulf Keystone Petroleum
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved